Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 51407-936

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 51407-936). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000 Tablets (Sacubitrilvalsartan 24 26 mg)

Label for Sacubitril and Valsartan Tablets, fil-coated, 24 mg/26 mg strength. The label indicates an oral dosage form with a package size of 1000 tablets. It is marketed by GSMS, Incorporated, Camarillo, CA, and includes storage instructions, dosage advisory, and a barcode. The label also displays the NDC number 51407-935-10.*

FDA Label Image

1000 Tablets (Sacubitrilvalsartan 49 51 mg1)

Label for Sacubitril and Valsartan Tablets containing 49 mg of sacubitril and 51 mg of valsartan per tablet. The oral film-coated tablets come in a bottle with 1000 count. The label includes storage instructions, dosage reference, and a barcode. Marketed by GSMS, Incorporated, Camarillo, CA.*

FDA Label Image

Figure 7 (Sacubitrilvalsartan 7 Figure)

A line graph comparing the hazard ratio of sacubitril and valsartan versus enalapril (PARADIGM-HF) and versus valsartan (PARAGON-HF). The x-axis shows left ventricular ejection fraction at screening (%) ranging approximately from 15 to 75. The y-axis shows hazard ratio values from 0.5 to 1.6. Solid lines represent hazard ratios and dashed lines indicate 95% confidence intervals for each comparison.*

FDA Label Image

1000 Tablets (Sacubitrilvalsartan 97 103 mg 1)

Label for sacubitril and valsartan tablets, film-coated, containing 97 mg sacubitril and 103 mg valsartan per tablet. The label shows strength prominently in a purple box, indicates a 1000 tablet count, and states the product is Rx only. It also includes storage instructions, marketing by GSMS, Incorporated, Camarillo, CA, and an NDC 51407-937-10.*

FDA Label Image

Sacubitrilvalsartan-fig-2 (Sacubitrilvalsartan Fig 2)

A comparative forest plot chart illustrating the geometric mean ratio and 90% confidence intervals of AUC and Cmax for LBQ657 and Valsartan across different population descriptions, including varying degrees of renal and hepatic impairment, age groups, gender, and ethnicities.*

FDA Label Image

Figure 1 (Sacubitrilvalsartan Fig1)

A forest plot chart showing the geometric mean ratio with 90% confidence intervals for AUC and Cmax of various coadministered drugs relative to a reference. Drugs listed include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil.*

FDA Label Image

Figure 3 (Sacubitrilvalsartan Fig3)

Three Kaplan-Meier curves showing cumulative failure rates (%) over time since randomization (days) comparing sacubitril and valsartan versus enalapril. Figure A depicts time to first occurrence of cardiovascular death or heart failure hospitalizations, Figure B shows time to occurrence of cardiovascular death, and Figure C shows time to first occurrence of heart failure hospitalizations. Each graph includes number at risk for both drugs at various time points.*

FDA Label Image

Figure 4 (Sacubitrilvalsartan Fig4)

A forest plot displaying hazard ratios (with 95% confidence intervals) comparing sacubitril and valsartan to enalapril across various patient subgroups. Subgroups include age, gender, weight, race, region, NYHA class, estimated GFR, diabetes status, systolic blood pressure, ejection fraction, atrial fibrillation, NT-proBNP level, hypertension, prior medication use, prior hospitalization, time since diagnosis, cause of heart failure, and presence of ICD devices. The plot visually contrasts efficacy outcomes between the two treatments.*

FDA Label Image

Figure 6 (Sacubitrilvalsartan Figur6)

A forest plot chart comparing the rate ratios of sacubitril and valsartan versus valsartan across various patient subgroups in a clinical study. The chart displays subgroups by age, sex, race, region, diabetic status, left ventricular ejection fraction (LVEF), atrial fibrillation, biomarkers, blood pressure, medication intolerance, kidney function, and heart failure classification, with corresponding numeric estimates and confidence intervals indicating comparative outcomes.*

FDA Label Image

Figure 5 (Sacubitrilvalsartan Figure5)

A line chart titled 'Total Heart Failure Hospitalizations and CV Death in PARAGON-HF' comparing mean number of events per 100 patients over time in days since randomization for two treatments: Valsartan and Sacubitril and Valsartan. The chart shows Sacubitril and Valsartan consistently having fewer events. A table below lists numbers at risk for each group at various time points up to 1440 days.*

FDA Label Image

Structure (Sacubitrilvalsartan Str)

Chemical structure of sacubitril and valsartan showing the detailed molecular arrangement, including sodium (Na) ions and water of hydration (H2O) as part of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.